Weber, Daniela D.
Aminzadeh-Gohari, Sepideh
Thapa, Maheshwor
Redtenbacher, Anna-Sophia
Catalano, Luca
Capelôa, Tânia
Vazeille, Thibaut
Emberger, Michael
Felder, Thomas K.
Feichtinger, René G.
Koelblinger, Peter
Dallmann, Guido
Sonveaux, Pierre
Lang, Roland
Kofler, Barbara
Article History
Received: 17 January 2022
Accepted: 28 June 2022
First Online: 18 July 2022
Declarations
:
: The animal xenograft studies were approved by the Salzburg Animal Care and Use Committee (Study approval no. 20901-TVG/122/6-2018). The animal allograft studies were approved by the Université catholique de Louvain (UCLouvain) authorities (Comité d’Ethique Facultaire pour l’Expérimentation Animale) (Study approval no. 2016/UCL/MD/018).
: Not applicable.
: G. D. and M. T. are employees of Biocrates Life Sciences AG. The company owns patents (EP1897014B1, EP1875401B1) describing the measurement technique of the commercially available MxP<sup>®</sup> Quant 500 kit used for the metabolomics measurements. P.K. has received honoraria for travel/congress support and consulting/advisory roles for Roche, Bristol Myers Squibb, Merck Sharp & Dome, Novartis, Amgen, Pierre Fabre, OMass Therapeutics, and Sanofi Aventis unrelated to the submitted work. R.L. has received research funding from Pierre Fabre and Roche for the submitted work and research funding from Bristol-Myers Squibb as well as honoraria and travel support from Merck Sharp & Dohme and travel support from Amgen outside the submitted work. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.